SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate

Business & Industry News Channel
AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77% (95% confidence interval (CI): 46, 90), compared to placebo.